HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: ERC-08-0170v1 15/4/885    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kaltsas, G. A Articles by Grossman, A. B Search for Related Content PubMed PubMed Citation Articles by Kaltsas, G. A Articles by Grossman, A. B

Endocrine Unit, Department of Pathophysiology, National University of Athens, Athens, Greece¹ Department of Academic Radiology, St Bartholomew's Hospital, London, UK² Department of Endocrinology, Theagenion Hospital, Thessaloniki, Greece³ Department of Endocrinology, St Bartholomew's Hospital, London EC1A 7BE, UK

(Correspondence should be addressed to A B Grossman; Email: a.b.grossman{at}qmul.ac.uk)

	Abstract

Top Abstract Introduction Anatomical considerations Clinical presentation Imaging Diagnosis Therapy Follow-up Summary Declaration of interest References

 
The sellar and parasellar region is an anatomically complex area where a number of neoplastic, inflammatory, infectious, developmental and vascular diseases can develop. Although most sellar lesions are due to pituitary adenomas, a number of other pathologies involving the parasellar region can present in a similar manner. The diagnosis of such lesions involves a multidisciplinary approach, and detailed endocrinological, ophthalmological, neuroimaging, neurological and finally histological studies are required. Correct diagnosis prior to any intervention is essential as the treatment of choice will be different for each disorder, particularly in the case of primary malignant parasellar tumours. The complexity of structures that define the parasellar region can produce a variety of neoplastic processes, the malignant potential of which relies on histological grading. In the majority of parasellar tumours, a multimodal therapeutic approach is frequently necessary including surgery, radiotherapy, primary or adjuvant medical treatment and replacement of apparent endocrine deficits. Disease-specific medical therapies are mandatory in order to prevent recurrence or further tumour growth. This is particularly important as neoplastic lesions of the parasellar region tend to recur after prolonged follow-up, even when optimally treated. Apart from the type of treatment, identification of clinical and radiological features that could predict patients with different prognosis seems necessary in order to identify high-risk patients. Due to their rarity, central registration of parasellar tumours is required in order to be able to provide evidence-based diagnostic and mainly therapeutic approaches.

	Introduction

Top Abstract Introduction Anatomical considerations Clinical presentation Imaging Diagnosis Therapy Follow-up Summary Declaration of interest References

 
The area immediately around the pituitary, the sellar and parasellar region, is an anatomically complex area that represents a crucial crossroads for important adjacent structures (Ruscalleda 2005). While the sellar region has specific anatomical landmarks, the parasellar region is not clearly delineated and includes all the structures that surround the sella turcica (Rennert & Doerfler 2007). Vital structures such as the brain parenchyma, meninges, visual pathways and other cranial nerves, major blood vessels, hypothalamo-pituitary system (HPS) and bony compartments may be involved. A diversity of clinical symptoms and signs can develop from a number of neoplastic, inflammatory, infectious, developmental and vascular diseases that occupy the parasellar area secondary to the location, size and growth potential of the lesions, and the subsequent damage to specific adjacent vital structures (Freda & Post 1999).

Pituitary adenomas are the most common cause of a sellar mass extending to the parasellar region (Freda & Post 1999). However, in 9% of cases, an aetiology other than a pituitary adenoma is encountered, parasellar tumours being the second commonest cause after non-tumorous cystic lesions (Freda et al. 1996). The malignant potential of these tumours may be defined according to the World Health Organization (WHO) classification of tumours of the central nervous system (CNS), which relies on histological criteria: WHO grade I (tumours with low proliferative potential and the possibility of cure following surgical resection), WHO grade II (infiltrative tumours with low mitotic activity that can recur and progress to higher grades of malignancy), WHO grade III (tumours with histological evidence of malignancy) and WHO grade IV (mitotically active tumours with rapid evolution of disease; Kleihues et al. 1993). The latest version of the WHO classification, including some new histologically identified variants that may have some clinical relevance, has recently been published (Louis et al. 2007). A number of other non-neoplastic lesions, such as inflammatory, granulomatous, infectious and/or vascular pathologies can also involve the parasellar region (Table 1).

	Anatomical considerations

Top Abstract Introduction Anatomical considerations Clinical presentation Imaging Diagnosis Therapy Follow-up Summary Declaration of interest References

 
The parasellar region includes, laterally, the dural walls of the cavernous sinus, a multi-lobulated venous structure containing the intracavernous portion of the internal carotid artery, cranial nerves III, IV, VI and the V₁ and V₂ branches of the trigeminal nerve (Smith 2005; Fig. 1). The relationships of the cavernous sinus are: inferiorly with the basisphenoid and sphenoid sinus; superiorly, the diaphragma sella, with the suprasellar subarachnoid spaces containing the optic nerves and chiasm, hypothalamus, tuber cinereum and anterior third ventricle (Ruscalleda 2005). The nasopharynx and the medial aspects of the temporal lobes are also closely related to the parasellar region; in addition, embryonal remnants can also be found contributing further to the diversity of the processes that are involved in delineating the anatomy of this region (Smith 2005).

View larger version (151K): [in this window] [in a new window]   Figure 1 Sagittal enhanced T1-weighted image of a hypothalamic glioma. This is partially cystic, partially solid and involves the chiasm and the hypothalamus.

	Clinical presentation

Top Abstract Introduction Anatomical considerations Clinical presentation Imaging Diagnosis Therapy Follow-up Summary Declaration of interest References

	Imaging

Top Abstract Introduction Anatomical considerations Clinical presentation Imaging Diagnosis Therapy Follow-up Summary Declaration of interest References

 
Radiological imaging of the parasellar region is challenging since the sella is a small volume region in close proximity to many complex structures (Ruscalleda 2005). Both thin-section computerised tomography (CT) and magnetic resonance imaging (MRI) play an important role in the anatomical delineation of lesions in this area (Boardman et al. 2008). MRI is the modality of choice providing multiplanar high-contrast images, whereas CT has a complementary role in delineating bony destruction and the visualisation of calcification (Rennert & Doerfler 2007). Conventional radiology is no longer in use, whereas digital subtraction angiography has been largely replaced by the continuous improvement in MR and CT angiographies (Rennert & Doerfler 2007). Although the radiological features of parasellar tumours have many similarities, some may have distinctive findings (Chong & Newton 1993, Freda & Post 1999, Ruscalleda 2005, Smith 2005; Table 2). However, the differential diagnosis among the various types of tumours remains difficult using currently available methods of morphological imaging.

	Diagnosis

Top Abstract Introduction Anatomical considerations Clinical presentation Imaging Diagnosis Therapy Follow-up Summary Declaration of interest References

	Therapy

Top Abstract Introduction Anatomical considerations Clinical presentation Imaging Diagnosis Therapy Follow-up Summary Declaration of interest References

 
Surgery remains the treatment of choice for benign tumours and malignant tumours that are not responsive to other forms of treatment, and/or when surgical debulking is essential (Day 2003, Glezer et al. 2008).

Surgical therapy

Parasellar tumours usually have irregular margins and adhere to vital neurovascular structures, and thus do not allow a complete resection without the danger of affecting critical brain areas (Couldwell et al. 2004). Resection is attempted by craniotomy and/or transsphenoidally (TSS), particularly for smaller tumours approachable through the sella (Baskin & Wilson 1986, Honegger et al. 1992). For massive lesions, a two-stage removal procedure may be necessary; initially TSS debulking followed by craniotomy later. This approach may allow residual tumour to descend inferiorly, facilitating further resection (Maira et al. 1995). Recently, the development of advanced cranial base TSS approaches has facilitated the exposure of basal lesions by the removal of osseous structures, minimising brain retraction and providing safe alternatives when assessing lesions involving the tuberculum sella, suprasellar region, cavernous sinus or clivus (Couldwell et al. 2004). The TSS route can also be used for midline lesions without significant lateral extension (Day 2003). In cases of hydrocephalus, resection may be achieved following decompression of the ventricles and stabilisation of the clinical status of the patient. In the presence of large cystic lesions, as with craniopharyngiomas, fluid aspiration can be applied first as may provide relief of the obstruction and facilitate further tumour removal (Karavitaki et al. 2006).

Radiotherapy (RT)

Conventional RT has traditionally been used either as primary treatment or as a way to prevent further tumour growth or recurrence (Brada & Cruickshank 1999, Perks et al. 1999). More sophisticated radiotherapeutic techniques have recently been introduced. Stereotactic radiosurgery delivers a single fraction of high-dose ionising radiation on mapped targets, keeping the exposure of adjuvant tissues to a minimum and allowing for the delivery of maximum tolerated dose of between 10 and 15 Gy (Giller & Berger 2005). Stereotactic RT combines the accurate focal delivery of stereotactic radiosurgery with the radiobiological advances of fractionation; compared with conventional RT, it minimises long-term toxicities by offering optimal sparing to surrounding tissue (Tarbell et al. 1994). Robotically controlled frameless radiosurgery has also been developed and studies assessing its efficacy are awaited (Giller et al. 2005). In general, RT seems to be a valuable asset in the treatment of these tumours, albeit with potential adverse effects to nearby tissue and the HPS (Brada & Cruickshank 1999).

Medical therapy

Chemotherapy remains the primary therapy for responsive malignant tumours in either a neoadjuvant or adjuvant setting following surgery and/or RT. Patients with infrequently curable or unresectable tumours should be considered candidates for clinical trials that evaluate interstitial brachytherapy, radiosensitisers, hyperthermia, or intraoperative radiation therapy in conjunction with external RT to improve local tumour control. Such patients are also candidates for studies that evaluate new drugs and biological response modifiers following RT. Therapy of established or evolving specific pituitary and hypothalamic hormonal deficits should be detected and adequately treated (Lamberts et al. 1998). Optimum hormonal replacement therapy should be aimed for, although even with replacement therapy parasellar tumours, particularly craniopharyngiomas, have a worse prognosis compared with pituitary adenomas (Tomlinson et al. 2001).

	Follow-up

Top Abstract Introduction Anatomical considerations Clinical presentation Imaging Diagnosis Therapy Follow-up Summary Declaration of interest References

 
Prognosis is dependent on patient status, comorbid conditions, tumour size and extension, and the precise histopathology. Children and adolescents should have careful monitoring of height, weight and pubertal status, while a dedicated neuroendocrine team should screen patients for endocrine and neuropsychological deficits at regular intervals. Post-operative imaging should be performed within 3 months of treatment and generally at 6 and 12 months to evaluate tumour recurrence or presence of residual tumour.

Malignant tumours of the parasellar region

Gliomas
Gliomas may arise in the hypothalamus, optic chiasm, nerve or tract (Zee et al. 2003; Fig. 1). The main histopathological subtype is the pilocytic astrocytoma (WHO grade I), which is a low-grade malignant lesion associated occasionally with neurofibromatosis type 1 (NF1; Zee et al. 2003). In this instance, lesions can be multiple including optic nerve gliomas, low-grade brain stem gliomas and basal ganglia non-neoplastic hamartomas (Zee et al. 2003). The remainder of hypothalamic/optic chiasm lesions are diffuse astrocytomas (WHO grade II), representing 35% of all astrocytic brain tumours (Smith 2005). This type of tumour typically affects young adults and has a tendency for malignant progression to anaplastic astrocytoma and, very rarely, glioblastoma (WHO grades III–VI). Hypothalamic/chiasmatic astrocytomas are primarily seen in adulthood presenting with impaired vision and retro orbital pain (Black & Pikul 1999). In children, they may present with visual loss, headache, proptosis and the diencephalic syndrome (Glezer et al. 2008). On imaging, hypothalamic/chiasmal gliomas are usually large suprasellar masses, infiltrating the brain and third ventricle, which enhance homogeneously; rarely, there is necrosis, haemorrhage or calcification (FitzPatrick et al. 1999). There is uncertainty as to the optimum therapy, and many can be simply observed; obviously, visual loss will determine the need for surgery. The mean survival time after surgical intervention is between 6 and 8 years, with considerable individual variation (Kitange et al. 2003). Optic pathway gliomas generally behave benignly, with very slow growth; however, tumours around the chiasm/hypothalamus can be more aggressive, exhibiting a 50% 5-year survival (Kitange et al. 2003).

Gliomas can also develop in the brainstem and extend into the parasellar region (Packer 2000, Guillamo et al. 2001). Diffuse intrinsic low-grade glioma (WHO grade II) is the most prominent type, whereas purely malignant brainstem glioma (WHO grades III–VI) occurs in 31% of cases (Guillamo et al. 2001). The median survival of low-grade gliomas is 7.3 years whereas that of high-grade gliomas was 11.2 months (Guillamo et al. 2001). Stereotactic biopsy has been reported to provide the diagnosis with minimal morbidity (Packer 2000). Although glucocorticoids and irradiation may temporarily improve symptoms, there seems to be no long-term benefit (Recinos et al. 2007). Occasionally, mixed gliomas may occur, for which temozolomide, an oral derivative of dacarbazine, may be useful therapy. Clinical improvement has been noted in 51% of patients, with a radiological response rate of 31% (Hoang-Xuan et al. 2004).

Germ cell tumours (GCTs)
Primary intracranial GCTs are neoplasms most commonly present in the first two decades of life (Janmohamed et al. 2002; Fig. 2). Like other extragonadal GCTs, CNS variants develop around the midline, with 80% arising around the third ventricle, mostly in the region of the pineal gland, followed by the suprasellar compartment and anterior hypothalamic regions (Jennings et al. 1985). Synchronous GCTs at both these sites are found at 5–10% (Jennings et al. 1985). Germinomatous GCT (GGCT) are the most exquisitely radiosensitive, whereas non-GGCT (NGGCT), comprising choriocarcinoma, teratoma, embryonal sinus (yolk sac) tumour and embryonal carcinoma, have a poorer overall response to treatment and a worse prognosis (Allen et al. 1987, Balmaceda et al. 1996). Non-GCT can also contain germinomatous elements (Calaminus et al. 2005). Pineal GCT classically give rise to raised IP, hydrocephalus and Parinaud's syndrome, whereas suprasellar GCT typically present with cranial DI, hypopituitarism and visual disturbance, and may lead to dissemination via the CSF (Legido et al. 1989, Janmohamed et al. 2002). Diagnosis is established by histology but a subgroup can be diagnosed on the basis of elevation of specific tumour markers (Calaminus et al. 2005), or typical clinical and radiological features. Yolk sac tumours secrete -fetoprotein and choriocarcinomas β-human chorionic gonadotrophin (β-hCG) that can be detected in the serum and/or CSF (Calaminus et al. 2005). Approximately 10% of germinomas may contain syncytiotrophoblastic elements and secrete β-hCG (Matsutani et al. 1997). Germinomas appear as large lesions typically slight hyperdense on CT that enhance after contrast medium administration (FitzPatrick et al. 1999). On MRI, they appear isointense to brain on T₁-weighted images and isointense-slightly hyperintense on T₂-weighted images (Rennert & Doerfler 2007).

View larger version (119K): [in this window] [in a new window]   Figure 2 Sagittal enhanced T1-weighted image of a germinoma with both a suprasellar and pineal enhancing mass lesions.

Treatment of GCT involves irradiation to the tumour bed to obtain local control, craniospinal irradiation to cover leptomeningeal tumour spread, and chemotherapy to eliminate leptomeningeal and systemic tumour dissemination (Gobel et al. 2001). When a pre-operative diagnosis of a GCT has been obtained, then surgical exploration is not necessary as these tumours are highly sensitive to chemotherapy and RT (Gobel et al. 2001, Janmohamed et al. 2002). Platinum-based chemotherapy has proven to be highly effective in non-seminomatous GCT (Allen 1987, Balmaceda et al. 1996) A cumulative dose of cis-platin of over 300 mg/m² and tumour bed irradiation dose of 50–54 Gy, together with craniospinal irradiation, has a synergistic effect and achieves a long-term relapse-free survival between 60 and 70% (Janmohamed et al. 2002, Calaminus et al. 2005). Neoadjuvant chemotherapy and delayed residual tumour resection may be more appropriate than primary tumour resection followed by the same chemotherapy (Janmohamed et al. 2002). The presence of CNS dissemination warrants more aggressive treatment, such as high-dose chemotherapy with stem-cell transplantation (Guillamo et al. 2001), or intraventicular treatment (Osuka et al. 2007). Two recent studies in children and adults have evaluated long-term treatment sequelae, revealing mainly impairment of endocrine function, and rare visual, hearing and neurological deficits (Legido et al. 1989). In general, our own approach has been to initiate treatment with chemotherapy in lesions that appear to be characteristic of germinomas, even in the absence of positive tumour markers, and then to re-image several weeks after initial chemotherapy; rapid shrinkage of the tumour will usually be confirmatory of the diagnosis, and the treatment completed.

Primary parasellar lymphomas
Primary CNS lymphomas account for less than 2% of all intracranial lesions (Fine & Mayer 1993; Fig. 3). By definition, these tumours are extranodal and arise primarily in the craniospinal axis, and are distinct from systemic lymphomas that secondarily metastasise to the CNS (Megan Ogilvie et al. 2005, Liu et al. 2007). Although initially described in immunocompromised patients, a significant increase in the incidence of such lesions has recently been documented in immunocompetent patients (Corn et al. 2000). Lymphomas involving the sellar/parasellar region are even rarer, representing less than 1% of all cases in a large cohort of patients who underwent TSS (Freda & Post 1999). Recently, the number of primary parasellar lymphomas has substantially increased, the majority being of B-cell origin and only a minority of T-cell origin; a case of a NK/T-cell lymphoma has also been reported (Liu et al. 2007). Approximately 18 patients with sellar/parasellar lymphomas have been described with a mean age at presentation of 55.5 years and male/female ratio of 13:5 (Fine & Mayer 1993, Liu et al. 2007). Endocrine abnormalities are relatively common, with 72% of patients exhibiting anterior, and 39% posterior, pituitary deficiencies respectively (Megan Ogilvie et al. 2005, Liu et al. 2007). In a recent review systemic symptoms, such as fever of unknown origin, were the presenting symptoms in 22% of patients, whereas the commonest presenting compressive symptoms were headache (56%), diplopia (39%) and visual field defects (28%) respectively (Liu et al. 2007). MRI may demonstrate enhancing parasellar masses with diffuse enlargement of the pituitary (94%), suprasellar extension (44%), cavernous sinus extension (39%) and stalk thickening (22%; Liu et al. 2007). Lymphomas usually appear iso- or hyperdense on CT scanning and isointense on T₁-weighted and slightly hypointense on T₂-weighted images and enhance homogeneously after gadolinium administration (Buhring et al. 2001). The diagnosis of primary lymphomas is established histologically and their treatment includes surgery, chemotherapy and RT according to established protocols (Megan Ogilvie et al. 2005, Glezer et al. 2008).

View larger version (122K): [in this window] [in a new window]   Figure 3 Coronal enhanced T1-weighted image of lymphoma. There is abnormal dural enhancement of both cavernous sinuses extending to involve the pituitary gland itself and with slight thickening of the stalk.

Supratentorial primitive neuroectodermal tumour is an embryonal tumour (WHO grade IV) of the cerebrum or suprasellar region composed of undifferentiated or poorly differentiated neuroepithelial cells, which have the capacity for differentiation along neuronal, astrocytic, ependymal, muscular or melanocytic lines (Ohba et al. 2008). Synonyms include cerebral medulloblastoma, cerebral neuroblastoma, cerebral ganglioneuroblastoma and ‘blue tumour’. This rare tumour occurs mainly in children with an overall 5-year survival rate of 34% (Ohba et al. 2008).

Ependymoblastoma is a rare, malignant, embryonal brain tumour (WHO grade IV) that occurs in neonates and young children. Ependymoblastomas are often large and supratentorial and generally relate to the ventricles, though they can occur in the parasellar region (Matthay et al. 2003). These types of tumours grow rapidly, with craniospinal dissemination, and have a fatal outcome within 6–12 months of diagnosis (Matthay et al. 2003).

Potentially malignant parasellar lesions

Craniopharyngiomas
Craniopharyngiomas are rare epithelial tumours that arise along the pathway of the craniopharyngeal duct (Bunin et al. 1998; Figs 4 and 5). They account for 2–5% of all primary intracranial neoplasms and follow a bimodal age distribution with a peak incidence rate in children and adults between the ages of 5 and 14 and 50 and 74 years respectively (Bunin et al. 1998). The majority show a suprasellar component (94–95%), and may extend into the anterior, middle or posterior fossa (Petito et al. 1976). Tumours can be solid (1–16%), but most are cystic or mixed (84–99%); cysts may be multiloculated and contain liquid that has high content of membrane lipids and cytokeratins (Karavitaki et al. 2006). Despite their benign histological appearance (WHO grade I), their infiltrative tendency into critical parasellar structures and aggressive behaviour, even after apparently successful treatment, heralds a significant morbidity and mortality (Karavitaki et al. 2006). Cases of malignant transformation have also been described, for which the role of previous RT has not been discounted (Nelson et al. 1988). There are two primary histological subtypes: the adamantinous and the papillary, but transitional or mixed forms have also been recognised (Zhang et al. 2002). The adamantinous subtype is the most common and bears some similarity to the adamantinoma of the jaw (Karavitaki et al. 2006), accounting for the calcification and the development of teeth encountered particularly in children (Petito et al. 1976). Adamantinous craniopharyngiomas tend to adhere to the surrounding brain tissue, often making complete surgical resection impossible (Petito et al. 1976). The papillary variety, mostly found in adults, is well circumscribed and shows less infiltration to adjacent tissues (Karavitaki et al. 2006). Although, headaches, nausea/vomiting, papillo-oedema, cranial nerve palsies and hydrocephalus are more frequent in children, a large series found no differences when compared the presenting manifestations among children and adults (Karavitaki et al. 2006). Spontaneous rupture of cystic craniopharyngioma is rare, but when it occurs can cause chemical ventriculitis and meningitis (Zee et al. 2003). Endocrine dysfunction in children manifests as growth failure in 93% or delayed sexual development in 20% (Freda & Post 1999). Many adults present with a variety of anterior pituitary hormone deficiencies and 23% develop DI (Freda & Post 1999). CT is the ideal modality for the evaluation of the bony anatomy, identification of calcification and in distinguishing the solid and cystic components of the tumour (Pusey et al. 1987). Pre- and post-contrast enhanced images identify the cystic lesions as a non-enhancing areas of low attenuation; the solid component and the cystic capsule appear as contrast-enhancing areas (Pusey et al. 1987). MRI following contrast enhancement offers valuable topographic and structural analysis (Karavitaki et al. 2006; Table 2). Radical surgery may be successful in selected tumours; however, when surgical removal was substantiated with radiological confirmation, complete removal was accomplished in 18–84% of cases, clearly a wide range (Hald et al. 1994). Post-operative RT following either complete or incomplete tumour removal is associated with significantly decreased recurrence rate; RT alone provides 10-year recurrence rates between 0 and 23% (Rajan et al. 1997). Although the optimum total dose or fractionated protocols have not been established, it seems that recurrences are fewer with total doses above 54 Gy (Karavitaki et al. 2006). Recurrent tumours develop at a mean interval between 1 and 4.3 years, but recurrences as late as 26 years have been described (Coke et al. 1998); such tumours exhibit higher microvessel density values (Vidal et al. 2002), and chromosomal aberrations (Lefranc et al. 2003). Stereotactic radiosurgery is used for well-defined residual tumour tissue after surgery or for the treatment of small solid recurrent tumours, especially after failure of conventional RT (Suh & Gupta 2006). In large cystic portions, multimodality approaches with installation of radioisotopes or bleomycin may provide further benefits (Karavitaki et al. 2006). Recurring tumours and those that have undergone malignant transformation have been treated with systemic chemotherapy and interferon-, albeit with short-lived results (Karavitaki et al. 2006). However, the treatment for aggressive tumours remains to be assessed by trials including large number of patients with adequate follow-up. In general, our own approach has been to attempt surgical removal, TSS where possible, but not to be radical where this may in any way compromise the hypothalamus; this would generally be followed by standard fractionated RT.

View larger version (101K): [in this window] [in a new window]   Figure 4 Sagittal unenhanced T1-weighted image of a craniopharyngioma. The mass is inseparable from the chiasm and hypothalamus and is predominantly of low T1 signal suggesting a cystic mass, although without a high lipid content.

View larger version (158K): [in this window] [in a new window]   Figure 5 Sagittal enhanced T1-weighted image of a solidly enhancing craniopharyngioma. This mass is inseparable from the hypothalamus and chiasm. There is an area of low signal within the mass representing calcification (confirmed on CT).

View larger version (113K): [in this window] [in a new window]   Figure 6 Coronal enhanced T1-weighted image of a chondrosarcoma. This is an enhancing mass involving the left side of the sella and the cavernous sinus, but arising from the skull base just off midline.

Haemangiopericytomas
Haemangiopericytomas are rare tumours accounting for less than 1% of all intracranial tumours (Glezer et al. 2008, Jalali et al. 2008). Although the majority are supratentorial, parasagittal or falcine, they can rarely arise in the sellar/parasellar region with less than ten cases reported (Jalali et al. 2008). These tumours are aggressive and highly vascular with numerous penetrating vessels; although previously considered as a subtype of angioblastic meningioma, they represent distinctive mesenchymal neoplasms arising from pericytes (Stout & Murray 1942). Besides the absence of firmly established histological criteria for grading haemangiopericytomas, they appear to correspond to WHO grades II–III (Kleihues et al. 1993). Most patients present in middle aged with visual field defects, headaches and rarely symptoms of endocrine dysfunction; a case of acromegaly due to a GHRH-secreting haemangiopericytoma has been described (Yokota et al. 1985). Surgery followed by RT is the standard treatment; however, as haemapericytomas are highly vascular and tend to bleed profusely, it is critical that the neurosurgeon bases his approach on a reasonable pre-operative diagnosis (Mena et al. 1991, Suh & Gupta 2006). Local tumour recurrence following treatment is common, and late widespread metastasis can occur (Jalali et al. 2008). In two large series haemangiopericytomas recurred in 91 and 85% after 15 years (Mena et al. 1991, Jalali et al. 2008). Cystic and necrotic areas, haemorrhage and prominent vascular channels contribute to the heterogeneity in signal intensity (Zee et al. 2003).

Langerhans' cell histiocytosis (LCH)
LCH is a rare disease characterised by the clonal accumulation and/or proliferation of specific dendritic cells and in this manner represents a neoplastic disorder (Arceci 1999; Fig. 7). LCH shows a particular predilection for involvement of the HPS leading to DI and/or anterior pituitary dysfunction (Arceci 1999, Makras et al. 2007), but can virtually involve any organ such as bone, lung, skin, liver, spleen, lymph nodes and bone marrow (Makras et al. 2007). Making an early and accurate diagnosis is important as multisystem LCH is associated with a 20% mortality rate, and 50% of those who survive develop at least one permanent consequence (Makras et al. 2007). Although there is no specific MRI appearance of HPS–LCH, almost all patients with LCH-induced DI demonstrate loss of the physiologic intense signal ‘bright spot’ of the posterior pituitary; other common MRI findings are infundibular enlargement, and/or the presence of hypothalamic mass lesions (Kaltsas et al. 2000). In cases where a precise diagnosis cannot be obtained histological diagnosis from the parasellar pathology may be required (Kaltsas et al. 2000). The combination of vinblastine with steroids is the most frequently used initial therapy of LCH involving the CNS and for multisystem disease (Arico et al. 2003). Although etoposide was initially extensively used, it is not used any long due to its associated high risk for the development of leukaemia (Arico et al. 2003). The purine analogue cladribine (2-chlorodeoxyadenosine, 2-CdA) has been shown to be effective for patients with recurrent and/or disseminated disease (Makras et al. 2007). RT, at doses up to 25 Gy, has been used in patients with endocrine deficiencies and radiological involvement of the parasellar region with partial or temporary radiological improvement (Arico et al. 2003).

View larger version (156K): [in this window] [in a new window]   Figure 7 Coronal enhanced T1-weighted image of Langerhans' cell histiocytosis. There is diffuse enlargement and enhancement of both cavernous sinuses. The pituitary gland is bulky, although the stalk is not thickened.

Meningiomas
Meningiomas (WHO grade I) are the most common non-glial primary brain tumour comprising 15% of primary brain tumours with a peak incidence between 40 and 70 years (Zee et al. 2003; Figs 8 and 9). Tumours arise from the diaphragma sella, tuberculum sella, medial lesser wing of sphenoid, anterior clinoid, clivus cavernous sinus or optic nerve sheath (Smith 2005). In 10–15% of cases, meningiomas arise from the parasellar region and represent the commonest tumour of that region after pituitary adenomas; rarely, they occur entirely within the sella mimicking a pituitary adenoma (FitzPatrick et al. 1999). There is a strong association between meningiomas, NF (multiple tumours) and ionising radiation, depending on the dose applied (Hartmann et al. 2006). The clinical presentation is usually with visual disturbance and occasionally endocrine dysfunction with mildly raised prolactin levels (Freda & Post 1999). The visual field defects vary and depend on the location of the tumour; meningiomas may increase in size during pregnancy and then become symptomatic (Freda & Post 1999). Atypical (WHO grade II) meningiomas may develop in 4–7%, whereas anaplastic tumours (WHO grade III) are seen in 1–2.8% of cases (Hartmann et al. 2006). However, malignant behaviour, although very rare, may occur with any grade of meningioma (Bruna et al. 2007, Ko et al. 2007). Imaging features of meningiomas frequently allow pre-operative diagnosis, distinguishing them from other parasellar tumours (Smith 2005). Lesions arise from the dura and have a broad attachment to the dura or fill and expand the cavernous sinus. There may be a linear, enhancing dural tail extending along the dura away from the lesion. Bone reaction, with bone thickening and sclerosis, or expansion of the sphenoid sinus air space, may also be seen (Smith 2005). Meningiomas typically are similar to grey matter in CT density and T₁- and T₂-weighted MR image signal intensity, enhancing homogeneously and brightly with occasional areas of diffuse calcification (Smith 2005). In contrast to other parasellar tumours, meningiomas encase blood vessels and tend to narrow the lumen (Young et al. 1988). Surgical excision, particularly in the presence of symptomatic or growing lesions, remains the treatment of choice (WHO I). Following surgical excision, grade I tumours recur in 7–20%, whereas atypical and anaplastic recur in 39–40% and 50–78% respectively (Bruna et al. 2007, Ko et al. 2007, Nakane et al. 2007). Surgery and RT is used in selected cases, such as for patients with known or suspected residual disease or with recurrence after previous surgery, whereas radiation alone is used in patients with unresectable tumours (Freda & Post 1999, Aghi & Barker 2006). The prognosis is worse for patients with WHO grades II and III tumours as complete resection is less common and the proliferative capacity is greater (Bruna et al. 2007, Ko et al. 2007, Nakane et al. 2007). Malignant histology is generally associated with a poor prognosis with a survival less than 2 years (Hartmann et al. 2006, Bruna et al. 2007, Nakane et al. 2007).

View larger version (163K): [in this window] [in a new window]   Figure 8 Sagittal enhanced T1-weighted image of a suprasellar meningioma. The mass lies above the pituitary (which is normal), involves the chiasm and extends anteriorly along the planum sphenoidale.

View larger version (144K): [in this window] [in a new window]   Figure 9 Coronal enhanced T1-weighted image of a meningioma in the left cavernous sinus. The meningioma enhances avidly, expands the cavernous sinus and is causing some narrowing of the left cavernous carotid artery, which is of smaller calibre than the right carotid.

View larger version (138K): [in this window] [in a new window]   Figure 10 Sagittal enhanced T1-weighted image of a Rathke's cleft cyst. The cyst is seen to be non-enhancing and lying on the superior aspect of the pituitary gland that appears flattened. It is causing elevation of the optic chiasm.

Hypothalamic hamartomas
Hypothalamic hamartomas are of neuronal origin and represent congenital heterotopias usually located within the tuber cinereum and mostly affecting children causing precocious puberty and epileptic seizures (Judge et al. 1977; Fig. 11). As they are usually less than 2 cm in diameter, they produce few symptoms of mass effect (Freeman et al. 2004). Typically, they appear as non-enhancing lesions and demonstrate rounded expansion of the tuber cinereum, best seen in coronal and sagittal images; they are isointense to the cerebral cortex in both T₁- and T₂-weighted MR images (Rennert & Doerfler 2007). The hamartomas associated with precocious puberty may contain GNRH1 neurons, and have been classically associated with ‘gelastic’ (laughing) seizures.

View larger version (148K): [in this window] [in a new window]   Figure 11 Sagittal enhanced T1-weighted image of a hypothalamic hamartoma. This is seen as a pedunculated mass hanging from the undersurface of the hypothalamus. It does not enhance and has the same signal as the grey matter of the brain parenchyma.

Lipoma
Lipomas are benign fatty tumours, derived from remnants of maldevelopment of the primitive meninx (Smith 2005; Fig. 12). In the sellar region, they occur as lesions adherent to the surface of the infundibulum, floor of the third ventricle or adjacent cranial nerves (Smith 2005). They are usually discovered incidentally but rarely may enlarge and produce symptoms. Lipomas are all well-circumscribed, homogeneous lesions that appear identical to fat on CT and all MRI sequences, do not enhance and usually exhibit rim calcification (Smith 2005).

View larger version (130K): [in this window] [in a new window]   Figure 12 Sagittal unenhanced T1-weighted image of a suprasellar lipoma. The high signal mass containing fat is seen lying on the undersurface of the hypothalamus in the interpeduncular cistern.

View larger version (104K): [in this window] [in a new window]   Figure 13 Coronal enhanced T1-weighted image of a left sided Schwannoma of the trigeminal nerve. There is an enhancing mass expanding the left cavernous sinus which followed the course of the trigeminal nerve on other images.

View larger version (147K): [in this window] [in a new window]   Figure 14 Sagittal enhanced T1-weighted image of a granular cell tumour. This enhancing mass lesion involves the pituitary stalk and the median eminence.

Rare parasellar tumours
Ependymomas are glial neoplasms that very rarely can develop in the parasellar region with only four cases described up to date; surgery with or without RT is the treatment of choice (Karim et al. 2006). Pituitocytoma is a primary tumour of the neurohypophysis, also located at the pituitary stalk, presenting with headache and hypopituitarism. Although histologically benign, the location and vascular nature of the tumour makes surgical resection difficult (Glezer et al. 2008). Other tumours such as plasmatocytomas, brown cell tumours and melanocytic tumours have been described as cases reports (Glezer et al. 2008).

Non-neoplastic pathologies involving the parasellar region

A number of non-neoplastic processes can also involve the parasellar region and present in a similar manner to parasellar neoplasms (Table 1). Their diagnosis is usually established in the presence of relevant clinical settings and if necessary histologically. Abscesses in the region can develop following direct extension from the sphenoid sinus, cavernous sinus and CSF or secondary to bacteraemia; masses of the sella can become secondarily infected (Freda et al. 1996). Tuberculosis can produce basilar meningitis and findings suggestive of a sellar/parasellar mass with hypopituitarism; there is usually evidence of tuberculosis elsewhere (Freda et al. 1996). Fungal, parasitic and opportunistic infections may also develop particularly in immunocompromised patients (Freda & Post 1999). Sarcoidosis can also present in a similar manner with varying degrees of hypopituitarism, DI and cranial neuropathy that in a minority can occur without evidence of sarcoidosis elsewhere (FitzPatrick et al. 1999). Other granulomatous diseases that can involve the parasellar region include giant cell granulomatous hypophysitis, Wegener's granulomatosis and the Tolosa–Hunt syndrome (Glezer et al. 2008). Aneurysms originating from the cavernous sinus or circle of Willis can project into the parasellar region and their appearance is mostly affected by the amount of calcification and thrombosis present within the aneurysms (Zee et al. 2003).

	Summary

Top Abstract Introduction Anatomical considerations Clinical presentation Imaging Diagnosis Therapy Follow-up Summary Declaration of interest References

 
The parasellar region can be affected by a variety of tumours. The presentation of these tumours can be similar to that of large non-functioning pituitary tumours with extensive extrasellar extension and other non-neoplastic lesions involving the same region. Although symptoms of mass effect to adjacent structures and anterior pituitary endocrine deficits do not distinguish parasellar tumours from non-functioning pituitary tumours, the presence of DI directs towards a non-pituitary aetiology. Considering the specific morphological characteristics of MRI and CT, a presumptive diagnosis is possible in many cases of parasellar lesions. However, in the majority of cases their diagnosis involves a multidisciplinary effort including detailed endocrinological, ophthalmological, neurological and imaging procedures. In cases of doubt, a histological diagnosis may still be required to allow appropriate treatment planning. Treatment involves a joint effort requiring the collaboration of different specialties. Although a significant number of parasellar tumours are slow growing and mostly benign, it is important to identify those which are malignant and/or exert a strong malignant potential. Surgical decompression and/or clearance of the tumour along with means to prevent recurrence and/or further tumour growth, such as RT, are usually applied. Specific hormonal replacement therapy of established or evolving endocrine deficits is required to maintain the patient's quality of life. Primary or adjuvant medical treatment may be necessary for malignant, recurrent tumours and/or tumours undergoing malignant transformation. Multidisciplinary teams for the management and support of patients with these tumours are required for better long-term results. Tumour-specific therapies are required and need to be addressed on the basis of tumoral biology. The central registration of patients seems necessary as it may provide correlates between forms of treatments and outcomes and establish prognostic factors at the pathological or molecular level.

	Declaration of interest

Top Abstract Introduction Anatomical considerations Clinical presentation Imaging Diagnosis Therapy Follow-up Summary Declaration of interest References

 
These authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

	Funding

 
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

	References

Top Abstract Introduction Anatomical considerations Clinical presentation Imaging Diagnosis Therapy Follow-up Summary Declaration of interest References

 
Aghi M & Barker FG 2006 Benign adult brain tumors: an evidence-based medicine review. Progress in Neurological Surgery 19 80–96.

Allan CA, Kaltsas G, Evanson J, Geddes J, Lowe DG, Plowman PN & Grossman AB 2001 Pituitary chondrosarcoma: an unusual cause of a sellar mass presenting as a pituitary adenoma. Journal of Clinical Endocrinology and Metabolism 86 386–391.[Abstract/Free Full Text]

Allen JC 1987 Management of primary intracranial germ cell tumors of childhood. Pediatric Neuroscience 13 152–157.[Medline]

Allen JC, Kim JH & Packer RJ 1987 Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous system. Journal of Neurosurgery 67 65–70.[Web of Science][Medline]

Arceci RJ 1999 The histiocytoses: the fall of the Tower of Babel. European Journal of Cancer 35 747–767.

Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, Emile JF, Lukina E, De Juli E & Danesino C 2003 Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. European Journal of Cancer 39 2341–2348.

Balmaceda C, Heller G, Rosenblum M, Diez B, Villablanca JG, Kellie S, Maher P, Vlamis V, Walker RW, Leibel S et al. 1996 Chemotherapy without irradiation – a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. Journal of Clinical Oncology 14 2908–2915.[Abstract]

Baskin DS & Wilson CB 1986 Surgical management of craniopharyngiomas. A review of 74 cases. Journal of Neurosurgery 65 22–27.[Web of Science][Medline]

Black KL & Pikul BK 1999 Gliomas-past, present, and future. Clinical Neurosurgery 45 160–163.[Medline]

Boardman JF, Rothfus WE & Dulai HS 2008 Lesions and pseudolesions of the cavernous sinus and petrous apex. Otolaryngologic Clinics of North America 41 195–213.[CrossRef][Medline]

Boari N, Losa M, Mortini P, Snider S, Terreni MR & Giovanelli M 2006 Intrasellar paraganglioma: a case report and review of the literature. Acta Neurochirurgica 148 1311–1314.[Medline]

Brada M & Cruickshank G 1999 Radiosurgery for brain tumours. BMJ 318 411–412.[Free Full Text]

Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P & Tortosa A 2007 Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 27 114–120.[Medline]

Buhring U, Herrlinger U, Krings T, Thiex R, Weller M & Kuker W 2001 MRI features of primary central nervous system lymphomas at presentation. Neurology 57 393–396.[Abstract/Free Full Text]

Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F & Bruner JM 1998 The descriptive epidemiology of craniopharyngioma. Journal of Neurosurgery 89 547–551.[Web of Science][Medline]

Calaminus G, Bamberg M, Harms D, Jurgens H, Kortmann RD, Sorensen N, Wiestler OD & Gobel U 2005 AFP/beta-HCG secreting CNS germ cell tumors: long-term outcome with respect to initial symptoms and primary tumor resection. Results of the cooperative trial MAKEI 89. Neuropediatrics 36 71–77.[CrossRef][Medline]

Chiang MF, Brock M & Patt S 1990 Pituitary metastases. Neurochirurgia 33 127–131.[Medline]

Chong BW & Newton TH 1993 Hypothalamic and pituitary pathology. Radiologic Clinics of North America 31 1147–1153.[Medline]

Cohen-Gadol AA, Pichelmann MA, Link MJ, Scheithauer BW, Krecke KN, Young WF Jr, Hardy J & Giannini C 2003 Granular cell tumor of the sellar and suprasellar region: clinicopathologic study of 11 cases and literature review. Mayo Clinic Proceedings 78 567–573.[Abstract/Free Full Text]

Coke CC, Corn BW, Werner-Wasik M, Xie Y & Curran WJ Jr 1998 Atypical and malignant meningiomas: an outcome report of seventeen cases. Journal of Neuro-Oncology 39 65–70.

Cone L, Srinivasan M & Romanul FC 1990 Granular cell tumor (choristoma) of the neurohypophysis: two cases and a review of the literature. American Journal of Neuroradiology 11 403–406.[Medline]

Corn BW, Dolinskas C, Scott C, Donahue B, Schultz C, Nelson DF & Fisher B 2000 Strong correlation between imaging response and survival among patients with primary central nervous system lymphoma: a secondary analysis of RTOG studies 83-15 and 88-06. International Journal of Radiation Oncology, Biology, Physics 47 299–303.[CrossRef][Medline]

Couldwell WT, Weiss MH, Rabb C, Liu JK, Apfelbaum RI & Fukushima T 2004 Variations on the standard transsphenoidal approach to the sellar region, with emphasis on the extended approaches and parasellar approaches: surgical experience in 105 cases. Neurosurgery 55 539–547.[CrossRef][Medline]

Day JD 2003 Surgical approaches to suprasellar and parasellar tumors. Neurosurgery Clinics of North America 14 109–122.[Medline]

Fine HA & Mayer RJ 1993 Primary central nervous system lymphoma. Annals of Internal Medicine 119 1093–1104.[Abstract/Free Full Text]

FitzPatrick M, Tartaglino LM, Hollander MD, Zimmerman RA & Flanders AE 1999 Imaging of sellar and parasellar pathology. Radiologic Clinics of North America 37 101–121.[Medline]

Freda PU & Post KD 1999 Differential diagnosis of sellar masses. Endocrinology and Metabolism Clinics of North America 28 81–117.[CrossRef][Medline]

Freda PU, Wardlaw SL & Post KD 1996 Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series. Journal of Clinical Endocrinology and Metabolism 81 3455–3459.[CrossRef][Medline]

Freeman JL, Coleman LT, Wellard RM, Kean MJ, Rosenfeld JV, Jackson GD, Berkovic SF & Harvey AS 2004 MR imaging and spectroscopic study of epileptogenic hypothalamic hamartomas: analysis of 72 cases. American Journal of Neuroradiology 25 450–462.[Abstract/Free Full Text]

Frighetto L, De Salles AA, Behnke E, Smith ZA & Chute D 2003 Image-guided frameless stereotactic biopsy sampling of parasellar lesions. Technical note. Journal of Neurosurgery 98 920–925.[Medline]

Giller CA & Berger BD 2005 New frontiers in radiosurgery for the brain and body. Proceedings 18 311–319.

Giller CA, Berger BD, Pistenmaa DA, Sklar F, Weprin B, Shapiro K, Winick N, Mulne AF, Delp JL, Gilio JP et al. 2005 Robotically guided radiosurgery for children. Pediatric Blood & Cancer 45 304–310.

Glezer A, Paraiba DB & Bronstein MD 2008 Rare sellar lesions. Endocrinology and Metabolism Clinics of North America 37 195–211.[CrossRef][Medline]

Gobel U, Schneider DT, Calaminus G, Jurgens H, Spaar HJ, Sternschulte W, Waag K & Harms D 2001 Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. Journal of Clinical Oncology 19 1943–1950.[Abstract/Free Full Text]

Guillamo JS, Doz F & Delattre JY 2001 Brain stem gliomas. Current Opinion in Neurology 14 711–715.[Medline]

Hald JK, Eldevik OP, Brunberg JA & Chandler WF 1994 Craniopharyngiomas – the utility of contrast medium enhancement for MR imaging at 1.5 T. Acta Radiologica 35 520–525.[Medline]

Hartmann C, Bostrom J & Simon M 2006 Diagnostic and molecular pathology of meningiomas. Expert Review of Neurotherapeutics 6 1671–1683.

Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Criniere E, Marie Y, Mokhtari K et al. 2004 Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. Journal of Clinical Oncology 22 3133–3138.[Abstract/Free Full Text]

Honegger J, Buchfelder M, Fahlbusch R, Daubler B & Dorr HG 1992 Transsphenoidal microsurgery for craniopharyngioma. Surgical Neurology 37 189–196.[CrossRef][Medline]

Ito I, Ishida T, Hashimoto T, Arita M, Osawa M, Yokota T & Ishimori T 2001 Hypopituitarism due to pituitary metastasis of lung cancer: case of a 21-year-old man. Internal Medicine 40 414–417.[CrossRef][Medline]

Jagannathan J, Kanter AS, Sheehan JP, Jane JA Jr & Laws ER Jr 2007 Benign brain tumors: sellar/parasellar tumors. Neurologic Clinics 25 1231–1249.[Medline]

Jalali R, Srinivas C, Nadkarni TD & Rajasekharan P 2008 Suprasellar haemangiopericytoma – challenges in diagnosis and treatment. Acta Neurochirurgica 150 67–71.[Medline]

Janmohamed S, Grossman AB, Metcalfe K, Lowe DG, Wood DF, Chew SL, Monson JP, Besser GM & Plowman PN 2002 Suprasellar germ cell tumours: specific problems and the evolution of optimal management with a combined chemoradiotherapy regimen. Clinical Endocrinology 57 487–500.[Medline]

Jennings MT, Gelman R & Hochberg F 1985 Intracranial germ-cell tumors: natural history and pathogenesis. Journal of Neurosurgery 63 155–167.[Web of Science][Medline]

Judge DM, Kulin HE, Page R, Santen R & Trapukdi S 1977 Hypothalamic hamartoma: a source of luteinizing-hormone-releasing factor in precocious puberty. New England Journal of Medicine 296 7–10.[Abstract]

Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drinkwater JE, Jenkins PJ, Monson JP, Besser GM & Grossman AB 2000 Hypothalamo-pituitary abnormalities in adult patients with Langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. Journal of Clinical Endocrinology and Metabolism 85 1370–1376.[Abstract/Free Full Text]

Karavitaki N, Cudlip S, Adams CB & Wass JA 2006 Craniopharyngiomas. Endocrine Reviews 27 371–397.[Abstract/Free Full Text]

Karim M, Sylvia A, Fred G & Patrick S 2006 Ependymoma of the pituitary fossa. Case report and review of the literature. Journal of Neurosurgery 105 616–620.[Medline]

Kitange GJ, Templeton KL & Jenkins RB 2003 Recent advances in the molecular genetics of primary gliomas. Current Opinion in Oncology 15 197–203.[CrossRef][Web of Science][Medline]

Kleihues P, Burger PC & Scheithauer BW 1993 The new WHO classification of brain tumours. Brain Pathology 3 255–268.[Web of Science][Medline]

Ko KW, Nam DH, Kong DS, Lee JI, Park K & Kim JH 2007 Relationship between malignant subtypes of meningioma and clinical outcome. Journal of Clinical Neuroscience 14 747–753.[Medline]

Komninos J, Vlassopoulou V, Protopapa D, Korfias S, Kontogeorgos G, Sakas DE & Thalassinos NC 2004 Tumors metastatic to the pituitary gland: case report and literature review. Journal of Clinical Endocrinology and Metabolism 89 574–580.[Abstract/Free Full Text]

Korten AG, ter Berg HJ, Spincemaille GH, van der Laan RT & Van de Wel AM 1998 Intracranial chondrosarcoma: review of the literature and report of 15 cases. Journal of Neurology, Neurosurgery, and Psychiatry 65 88–92.[Abstract/Free Full Text]

Kunanandam V & Gooding MR 1995 Parasellar chondrosarcoma: total excision improves prognosis. British Journal of Neurosurgery 9 87–91.[CrossRef][Medline]

Laigle-Donadey F, Taillibert S, Martin-Duverneuil N, Hildebrand J & Delattre JY 2005 Skull-base metastases. Journal of Neuro-Oncology 75 63–69.

Lamberts SW, de Herder WW & van der Lely AJ 1998 Pituitary insufficiency. Lancet 352 127–134.[Web of Science][Medline]

Lefranc F, Chevalier C, Vinchon M, Dhellemmes P, Schuring MP, Kaltner H, Brotchi J, Ruchoux MM, Gabius HJ, Salmon I et al. 2003 Characterization of the levels of expression of retinoic acid receptors, galectin-3, macrophage migration inhibiting factor, and p53 in 51 adamantinomatous craniopharyngiomas. Journal of Neurosurgery 98 145–153.[Medline]

Legido A, Packer RJ, Sutton LN, D'Angio G, Rorke LB, Bruce DA & Schut L 1989 Suprasellar germinomas in childhood. A re appraisal. Cancer 63 340–344.

Liu JK, Sayama C, Chin SS & Couldwell WT 2007 Extranodal NK/T-cell lymphoma presenting as a pituitary mass. Case report and review of the literature. Journal of Neurosurgery 107 660–665.[Medline]

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW & Kleihues P 2007 The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 114 97–109.[CrossRef][Medline]

Maira G, Anile C, Rossi GF & Colosimo C 1995 Surgical treatment of craniopharyngiomas: an evaluation of the transsphenoidal and pterional approaches. Neurosurgery 36 715–724.[Medline]

Makras P, Alexandraki KI, Chrousos GP, Grossman AB & Kaltsas GA 2007 Endocrine manifestations in Langerhans cell histiocytosis. Trends in Endocrinology and Metabolism 18 252–257.[Medline]

Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O, Funata N & Seto T 1997 Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. Journal of Neurosurgery 86 446–455.[Web of Science][Medline]

Matthay KK, Brisse H, Couanet D, Couturier J, Benard J, Mosseri V, Edeline V, Lumbroso J, Valteau-Couanet D & Michon J 2003 Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer 98 155–165.[CrossRef][Medline]

Megan Ogilvie C, Payne S, Evanson J, Lister TA & Grossman AB 2005 Lymphoma metastasizing to the pituitary: an unusual presentation of a treatable disease. Pituitary 8 139–146.[Medline]

Mena H, Ribas JL, Pezeshkpour GH, Cowan DN & Parisi JE 1991 Hemangiopericytoma of the central nervous system: a review of 94 cases. Human Pathology 22 84–91.[CrossRef][Web of Science][Medline]

Meyers SP, Hirsch WL Jr, Curtin HD, Barnes L, Sekhar LN & Sen C 1992 Chondrosarcomas of the skull base: MR imaging features. Radiologica 184 103–108.

Morita A, Meyer FB & Laws ER Jr 1998 Symptomatic pituitary metastases. Journal of Neurosurgery 89 69–73.[Medline]

Mukherjee JJ, Islam N, Kaltsas G, Lowe DG, Charlsworth M, Afshar F, Trainer PJ, Monson JP, Besser GM & Grossman AB 1997 Clinical, radiological and pathological features of patients with Rathke's cleft cysts: tumors that may recur. Journal of Clinical Endocrinology and Metabolism 82 2357–2362.[Abstract/Free Full Text]

Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S, Saito K & Yoshida J 2007 Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. Journal of Neurosurgery 107 398–404.[Medline]

Nelson GA, Bastian FO, Schlitt M & White RL 1988 Malignant transformation in craniopharyngioma. Neurosurgery 22 427–429.[Medline]

Ohba S, Yoshida K, Hirose Y, Ikeda E & Kawase T 2008 A supratentorial primitive neuroectodermal tumor in an adult: a case report and review of the literature. Journal of Neuro-Oncology 86 217–224.

Osuka S, Tsuboi K, Takano S, Ishikawa E, Matsushita A, Tokuuye K, Akine Y & Matsumura A 2007 Long-term outcome of patients with intracranial germinoma. Journal of Neuro-Oncology 83 71–79.

Packer RJ 2000 Chemotherapy: low-grade gliomas of the hypothalamus and thalamus. Pediatric Neurosurgery 32 259–263.[CrossRef][Medline]

Packer RJ, Cohen BH & Cooney K 2000 Intracranial germ cell tumors. Oncologist 5 312–320.[Abstract/Free Full Text]

Perks JR, Jalali R, Cosgrove VP, Adams EJ, Shepherd SF, Warrington AP & Brada M 1999 Optimization of stereotactically-guided conformal treatment planning of sellar and parasellar tumors, based on normal brain dose volume histograms. International Journal of Radiation Oncology, Biology, Physics 45 507–513.[Medline]

Petito CK, DeGirolami U & Earle KM 1976 Craniopharyngiomas: a clinical and pathological review. Cancer 37 1944–1952.

Pusey E, Kortman KE, Flannigan BD, Tsuruda J & Bradley WG 1987 MR of craniopharyngiomas: tumor delineation and characterization. American Journal of Roentgenology 149 383–388.[Abstract/Free Full Text]

Rajan B, Ashley S, Thomas DG, Marsh H, Britton J & Brada M 1997 Craniopharyngioma: improving outcome by early recognition and treatment of acute complications. International Journal of Radiation Oncology, Biology, Physics 37 517–521.[CrossRef][Medline]

Recinos PF, Sciubba DM & Jallo GI 2007 Brainstem tumors: where are we today? Pediatric Neurosurgery 43 192–201.[Medline]

Rennert J & Doerfler A 2007 Imaging of sellar and parasellar lesions. Clinical Neurology and Neurosurgery 109 111–124.[Medline]

La Rocca RV, Morgan KW, Paris K & Baeker TR 1999 Recurrent chondrosarcoma of the cranial base: a durable response to ifosfamide–doxorubicin chemotherapy. Journal of Neuro-Oncology 41 281–283.

Rosenberg AE, Brown GA, Bhan AK & Lee JM 1994 Chondroid chordoma – a variant of chordoma. A morphologic and immunohistochemical study. American Journal of Clinical Pathology 101 36–41.[Medline]

Ruelle A, Palladino M & Andrioli GC 1992 Pituitary metastases as presenting lesions of malignancy. Journal of Neurosurgical Sciences 36 51–54.[Medline]

Ruscalleda J 2005 Imaging of parasellar lesions. European Radiology 15 549–559.[CrossRef][Medline]

Salisbury JR & Isaacson PG 1986 Distinguishing chordoma from chondrosarcoma by immunohistochemical techniques. Journal of Pathology 148 251–252.[CrossRef][Medline]

Samandouras G, Kerr RS & Milford CA 2005 Minimally invasive biopsy of parasellar lesions: safety and clinical applications of the endoscopic, transnasal approach. British Journal of Neurosurgery 19 338–344.[Medline]

Sioutos P, Yen V & Arbit E 1996 Pituitary gland metastases. Annals of Surgical Oncology 3 94–99.[Abstract]

Smith JK 2005 Parasellar tumors: suprasellar and cavernous sinuses. Topics in Magnetic Resonance Imaging 16 307–315.[CrossRef][Medline]

Steel TR, Dailey AT, Born D, Berger MS & Mayberg MR 1993 Paragangliomas of the sellar region: report of two cases. Neurosurgery 32 844–847.[Medline]

Stout AP & Murray MR 1942 Hemangiopericytoma: a vascular tumour featuring Zimmermann's pericytes. Annals of Surgery 116 26–33.[Web of Science][Medline]

Suh JH & Gupta N 2006 Role of radiation therapy and radiosurgery in the management of craniopharyngiomas. Neurosurgery Clinics of North America 17 143–148.

Tarbell NJ, Barnes P, Scott RM, Goumnerova L, Pomeroy SL, Black PM, Sallan SE, Billett A, LaVally B, Helmus A et al.Advances in radiation therapy for craniopharyngiomasPediatric Neurosurgery 21 Supplement_1 1994 101–107.

Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC & Stewart PM 2001 Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357 425–431.[CrossRef][Web of Science][Medline]

Vidal S, Kovacs K, Lloyd RV, Meyer FB & Scheithauer BW 2002 Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome. Cancer 94 738–745.

Yokota M, Tani E, Maeda Y, Morimura T, Kakudo K & Uematsu K 1985 Acromegaly associated with suprasellar and pulmonary hemangiopericytomas. Case report. Journal of Neurosurgery 62 767–771.[Medline]

Young SC, Grossman RI, Goldberg HI, Spagnoli MV, Hackney DB, Zimmerman RA & Bilaniuk LT 1988 MR of vascular encasement in parasellar masses: comparison with angiography and CT. American Journal of Neuroradiology 9 35–38.[Abstract]

Zee CS, Go JL, Kim PE, Mitchell D & Ahmadi J 2003 Imaging of the pituitary and parasellar region. Neurosurgery Clinics of North America 14 55–80.[Medline]

Zhang YQ, Wang CC & Ma ZY 2002 Pediatric craniopharyngiomas: clinicomorphological study of 189 cases. Pediatric Neurosurgery 36 80–84.[CrossRef][Medline]

This Article Abstract Full Text (PDF) All Versions of this Article: ERC-08-0170v1 15/4/885    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kaltsas, G. A Articles by Grossman, A. B Search for Related Content PubMed PubMed Citation Articles by Kaltsas, G. A Articles by Grossman, A. B